Evaluating the Short-Term Cost-Effectiveness of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Failing Metformin Monotherapy in the United States

por Langer, Jakob, Hunt, Barnaby, Valentine, William J.
Publicado 2013

Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands

por Hunt, Barnaby, Glah, Divina, van der Vliet, Maarten
Publicado 2017

Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom

por Hunt, Barnaby, Ye, Qing, Valentine, William J., Ashley, Donna
Publicado 2017

Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA

por Hunt, Barnaby, Mocarski, Michelle, Valentine, William J., Langer, Jakob
Publicado 2017

IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting

por Hunt, Barnaby, Mocarski, Michelle, Valentine, William J., Langer, Jakob
Publicado 2017

Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA

por Hunt, Barnaby, Mocarski, Michelle, Valentine, William J., Langer, Jakob
Publicado 2017

Evaluation of the cost per patient per injection of botulinum toxin A in upper limb spasticity: comparison of two preparations in 19 countries

por Roze, Stéphane, Kurth, Hannah, Hunt, Barnaby, Valentine, William, Marty, Rémi
Publicado 2012

Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic

por Kvapil, Milan, Prázný, Martin, Holik, Pavel, Rychna, Karel, Hunt, Barnaby
Publicado 2017

Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi

por Pöhlmann, Johannes, Russel-Szymczyk, Monika, Holík, Pavel, Rychna, Karel, Hunt, Barnaby
Publicado 2019

Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting

por Capehorn, Matthew, Hallén, Nino, Baker-Knight, James, Glah, Divina, Hunt, Barnaby
Publicado 2021

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK

por Evans, Marc, Berry, Sasha, Malkin, Samuel J. P., Hunt, Barnaby, Sharma, Abheet
Publicado 2023

Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy

por Ren, Hongye, Berry, Sasha, Malkin, Samuel Joseph Paul, Hunt, Barnaby, Bain, Stephen
Publicado 2023

Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden

por Jendle, Johan, Ericsson, Åsa, Hunt, Barnaby, Valentine, William J., Pollock, Richard F.
Publicado 2017

The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): A sho...

por Drummond, Russell, Malkin, Samuel, Du Preez, Michelle, Lee, Xin Ying, Hunt, Barnaby
Publicado 2018

Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy

por Pöhlmann, Johannes, Montagnoli, Roberta, Lastoria, Giusi, Parekh, Witesh, Markert, Marie, Hunt, Barnaby
Publicado 2019

The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal

por Malkin, Samuel J. P., Carvalho, Davide, Costa, Catarina, Conde, Vasco, Hunt, Barnaby
Publicado 2022

Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses

por Rouzier, Roman, Pronzato, Paolo, Chéreau, Elisabeth, Carlson, Josh, Hunt, Barnaby, Valentine, William J.
Publicado 2013

Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia

por Malkin, Samuel J. P., Russel-Szymczyk, Monika, Liidemann, Girtel, Volke, Vallo, Hunt, Barnaby
Publicado 2018

Evaluation of the long‐term cost‐effectiveness of once‐weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK

por Viljoen, Adie, Hoxer, Christina S., Johansen, Pierre, Malkin, Samuel, Hunt, Barnaby, Bain, Stephen C.
Publicado 2018

The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia

por Malkin, Samuel J. P., Russel-Szymczyk, Monika, Psota, Marek, Hlavinkova, Lucia, Hunt, Barnaby
Publicado 2019